Bank of New York Mellon Corp Sells 755,041 Shares of Edwards Lifesciences Corporation $EW

Bank of New York Mellon Corp cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,737,548 shares of the medical research company’s stock after selling 755,041 shares during the period. Bank of New York Mellon Corp’s holdings in Edwards Lifesciences were worth $1,340,343,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. State Street Corp increased its position in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Edwards Lifesciences by 4.8% in the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after buying an additional 989,533 shares during the last quarter. Norges Bank acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $803,686,000. Morgan Stanley grew its stake in shares of Edwards Lifesciences by 12.4% in the fourth quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock valued at $623,544,000 after buying an additional 804,942 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Edwards Lifesciences by 66.1% in the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after buying an additional 2,359,128 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the topic of several analyst reports. Citigroup upped their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. BTIG Research lifted their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. Finally, TD Cowen reaffirmed a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $98.73.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,816,861.34. This represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,577 shares of company stock worth $3,855,527. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $87.22 on Thursday. The firm has a market cap of $50.22 billion, a P/E ratio of 46.39, a price-to-earnings-growth ratio of 2.26 and a beta of 0.86. The business’s 50 day moving average is $87.12 and its 200-day moving average is $83.92. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.